BioSpace News Archive

Dyne Therapeutics, Inc. (Nasdaq: DYN) today announced that new preclinical data demonstrating the FORCE™ platform achieved delivery to the central nervous system (CNS) and robust pharmacological effects in the brain will be featured in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, announced today that it will share initial preclinical data on its in vivo Gene Placement System (iGPS™) technology during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

2seventy bio, Inc. (Nasdaq: TSVT) today announced the presentation of five abstracts, including one late-breaking oral presentation, at this year’s American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, California from May 16-20, 2023.

MannKind Corporation will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM on Tuesday, May 9, 2023.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

BrightPath Biotherapeutics Co., Ltd. (TYO: 4594) and Artisan Bio. Inc today announced they have signed a research and licensing agreement to accelerate BrightPath’s next-generation iNKT cell therapies to clinic.

CANbridge Pharmaceuticals Inc. announced that data on the novel second-generation gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, will be presented at the American Society of Gene and Cell Therapy 26th Annual Meeting, May 16-20, Los Angeles, CA.

LeMaitre, a provider of vascular devices, implants and services, reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

Morphic Holding, Inc., a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, announced a proposed underwritten public offering of its common stock.